SEC Form 4 · accession 0000899243-19-005964
Kaleido Biosciences, Inc. · KLDO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael W Bonney
Officer — Executive Chair · Director
Period of report
Feb 28, 2019
Accepted (ET)
Mar 4, 2019 · 8:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001751299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Feb 28, 2019 | P | 68,965 | $13.95 | A | 1,005,968 | D | |
| Common StockF3 | Feb 28, 2019 | P | 2,555 | $14.65 | A | 1,008,523 | D | |
| Common StockF1 | Mar 4, 2019 | C | 417,673 | — | A | 1,426,196 | D | |
| Common StockF1,F4 | Mar 4, 2019 | C | 225,000 | — | A | 225,000 | I | See Foonote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series B Preferred StockF1 | — | Mar 4, 2019 | C | 835,347 | D | — | — | Common Stock | 417,673 | 0 | D |
| Series B Preferred StockF1,F4 | — | Mar 4, 2019 | C | 450,000 | D | — | — | Common Stock | 225,000 | 0 | I |
Explanation of responses
- F1Each share of Series B Preferred Stock converted into shares of the Issuer's common stock, par value $0.001 ("Common Stock"), on a one-for-two basis upon the closing of the Issuer's initial public offering.
- F2The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.50 to $14.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F3The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.52 to $14.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F4Shares held in the Michael and Alison Bonney 2016 Irrevocable Trust, which has an independent trustee.